sponsored
PatientsVille.com Logo

PatientsVille

Immunosuppression Medical Research Studies

Up-to-date List of Immunosuppression Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Immunosuppression Medical Research Studies

Rank Status Study
1 Recruiting Effect of RANKL Inhibition on UV-induced IMMUNOSUPPRESSION
Conditions: Ultraviolet Rays;   IMMUNOSUPPRESSION;   Hypersensitivity, Delayed;   Immune Tolerance/Drug Effects
Interventions: Drug: Denosumab;   Radiation: UVB exposure;   Drug: Diphenylcyclopropenone;   Drug: Normal Saline
Outcome Measures: Change in dermal thickness: denosumab group vs placebo group of Cohort 2;   Clinical score of contact hypersensitivity reactions: denosumab group vs placebo group of Cohort 2;   Diameters of contact hypersensitivity reactions: denosumab group vs placebo group of Cohort 2;   Change in dermal thickness: non UV-exposed (Cohort 1) vs UV-exposed (Cohort 2);   Clinical score of contact hypersensitivity reactions: non UV-exposed (Cohort 1) vs UV-exposed (Cohort 2);   Diameters of contact hypersensitivity reactions: non UV-exposed (Cohort 1) vs UV-exposed (Cohort 2);   Gene expression levels: denosumab group vs placebo group of Cohort 2;   Histological pattern of expression of RANKL and other proteins of interest: denosumab group vs placebo group of Cohort 2
2 Unknown  Withdrawal of IMMUNOSUPPRESSION in Long Term Stable Liver Transplant Recipients
Condition: Liver Transplantation
Interventions: Procedure: IMMUNOSUPPRESSION withdrawal;   Procedure: continue of taking immunosuppressant
Outcome Measures: number of participants who have the potential for the operational tolerance;   Tolerance biomarker;   immunologic profile related to rejection
3 Recruiting Steroid Free IMMUNOSUPPRESSION or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen
Conditions: Renal Insufficiency;   Kidney Transplantation
Intervention: Drug: tacrolimus OD, mycophenolic acid, prednisolone
Outcome Measures: renal function parameters;   tubular atrophy and interstitial fibrosis;   rejection episodes;   graft and patient survival;   cardiovascular incidents;   infectious complications;   dexa bone densitometry
4 Recruiting Individually Adapted IMMUNOSUPPRESSION in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study
Condition: Kidney Transplantation
Interventions: Drug: individual adapted IMMUNOSUPPRESSION;   Drug: golden standard therapy
Outcome Measures: Graft function as measured by Cr EDTA AUC;   Graft survival;   Patient survival;   Graft function measured by estimated GFR (eGFR) (MDRD and Cockroft-Gault);   Frequency of biopsy proven acute rejection episodes;   Incidence of biopsy proven acute rejection (BPAR) and clinical (non-biopsy proven) acute rejection episodes treated by a full course anti-rejection therapy (e.g. steroids) (Treatment of rejection according to center practice).;   Incidence of rejection treated by antibodies (OKT3, ATG);   Time to first rejection (days);   Severity of rejection as assessed by BANFF 2005 score;   Number of acute rejections per patient;   Plasma creatinine and eGFR;   Measured GFR;   Proteinuria;   Incidence and score of borderline changes and acute rejection;   Incidence and score of chronic alloimmune injury/rejection and nonimmune injury;   Development and evolution of glucose abnormalities;   blood pressure;   ambulatory 24-hr blood pressure monitoring;   Left ventricular mass assessed by echocardiography;   Fasting lipid profile;   CMV infection (as measured with whole blood PCR) and disease;   Polyoma virus replication as measured by whole blood PCR;   Incidence of BK nephritis;   Incidence of PTLD and Nonmelanoma skin cancer;   Incidence of EBV reactivation (as measured with whole blood PCR)
5 Not yet recruiting Studying the Effect of Changing IMMUNOSUPPRESSION in Case of Polyoma BK Virus Infection of the Renal Transplant
Conditions: Disorder Related to Renal Transplantation;   IMMUNOSUPPRESSION Related Infectious Disease;   Virus Diseases
Interventions: Drug: mTOR inhibitor (everolimus);   Drug: cyclosporine or tacrolimus
Outcome Measures: death or graft loss;   decrease of polyomavirus serum PCR;   decrease of creatinine;   progression of chronic changes in renal histology;   number of rejections following intervention;   increase of BKV-specific T-cells
6 Unknown  Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in IMMUNOSUPPRESSION w/CSA & Mycophenolate Mofetil
Condition: Post Transplant in IMMUNOSUPPRESSION w/CSA & Mycophenolate Mofetil
Intervention: Drug: Mycophenolate Mofetil
Outcome Measure: Efficacy
7 Recruiting Human Upper Extremity Allotransplantation
Conditions: Amputation, Traumatic;   Wounds and Injuries;   Hand Injuries
Interventions: Procedure: Deceased donor hand transplantation;   Drug: Bone marrow cell-based therapy & single-drug IMMUNOSUPPRESSION.
Outcome Measures: Graft Survival;   Documentation of IMMUNOSUPPRESSION required by transplanted participants to maintain graft.
8 Recruiting HLA-Identical Sibling Renal Transplant Tolerance
Conditions: IMMUNOSUPPRESSION;   Kidney Transplantation;   Graft Rejection
Intervention: Biological: Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Outcome Measures: The ability to withdraw IMMUNOSUPPRESSION as above 24 months post-transplant with follow-up to 10 years.;   Patient and graft survival measured at the one-year timepoint post-transplant.;   Patient and graft survival measured at the three year timepoint post-transplant..;   Incidence rate of biopsy-proven acute rejection, defined as a renal biopsy demonstrating acute cellular or humoral rejection of Banff Grade IA or greater.;   Incidence of chronic allograft nephropathy, determined using renal biopsies and laboratory values, including 24 hour urine protein excretion.;   Incidence of graft versus host disease (GVHD).;   Incidence of adverse events associated w/ renal transplantation and IMMUNOSUPPRESSION, including infections, malignancies, post transplant lymphoproliferative disease (PTLD), thromboembolic events, hyperlipidemia, leukopenia, thrombocytopenia, GI toxic
9 Recruiting Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free IMMUNOSUPPRESSION After Renal Transplantation
Condition: Disorder Related to Renal Transplantation
Interventions: Drug: Basiliximab, Tacrolimus, MMF, Prednisolon;   Drug: Basiliximab, Tacrolimus, MMF;   Drug: Tacrolimus, MMF, rATG
Outcome Measures: Efficacy of IMMUNOSUPPRESSION measured in rejection rate confirmed by biopsy according to BANFF 97, modified 2005.;   Rate of patients with steroid-free IMMUNOSUPPRESSION;   patient and graft survival rate;   graft function (calculated by the Cock- croft-Gault and MDRD-IV formula respectively calculated creatinine clearance by the Nankivell formula respectively cystatin C measurement);   Number of steroid-resistant rejections;   blood pressure level and also amount and types of blood pressure medications;   Lipid levels and also amount and types of lipid-lowering medications;   body weight, relative weight gain [kg], BMI;   infection rate, infection type and infection severity;   anemia requiring erythropoietin treatment;   PTLD incidence;   tumor incidence;   incidence of diabetes mellitus nd incidence of abnormal fasting blood sugar levels respectively incidence of impaired glucose tolerance, incidence of de novo insulin-requiring or oral-antidiabetic-requiring treatment over ≥30 days;   incidence of cataracts;   incidence of avascular necrosis;   incidence of osteoporosis;   Wound healing disorders;   incidence of chronic allograft nephropathy (CAN) (12-month histology);   incidence of CMV disease (qPCR >1000 copies/μL);   incidence of BKV disease (qPCR >1000 copies/μL);   incidence of EBV disease (qPCR >1000 copies/μL)
10 Recruiting Multicenter Study of Peritransplantation IMMUNOSUPPRESSION for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Condition: Patients Receiving Mismatched Allogeneic HCT
Intervention: Drug: IMMUNOSUPPRESSION
Outcome Measures: Treatment related mortality;   Toxicity according CTC of protocol on day 100;   Engraftment on day 100;   Overall survival;   Incidence of graft versus host disease;   Incidence of infections;   Immune reconstitution of CD3, CD3/CD4/CD8, CD56, CD19 cells;   Disease free survival;   Disease response
11 Recruiting IMMUNOSUPPRESSION in Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: Basiliximab;   Drug: Methylprednisolone;   Drug: Prednisone;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
Outcome Measures: Change in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R);   Change in Slow Vital Capacity (SVC);   Change in Hand-Held Dynamometry (HHD);   Change in Cytokine levels in Cerebrospinal Fluid (CSF);   Collection of peripheral blood mononuclear cells (PBMCs) in Blood;   Change in Left Grip Strength;   Change in Right Grip Strength;   Change in Antibody levels in Cerebrospinal Fluid (CSF);   Collection of Ribonucleic Acid (RNA) in Blood
12 Recruiting Thymoglobulin Induction Therapy With Minimal IMMUNOSUPPRESSION and Evaluation of Allograft Status
Conditions: Kidney Transplant;   IMMUNOSUPPRESSION
Intervention: Drug: Tacrolimus
Outcome Measures: The primary endpoint will be a composite of the following: biopsy-confirmed acute rejection and progression of histologically proven chronic allograft nephropathy at 15 months after transplantation.;   Patient survival;   Graft survival;   Incidence and severity of chronic allograft nephropathy;   Renal function (estimated glomerular filtration rate);   Perforin and granzyme B mRNA levels in urine;   Time to acute rejection;   Severity of acute rejection (by Banff criteria and need for anti-lymphocyte agents to treat acute rejection);   Incidence of opportunistic infection;   Development of new onset diabetes mellitus
13 Recruiting Effects of Zortress® + Tacrolimus vs. Standard IMMUNOSUPPRESSION on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
Condition: Renal Transplant
Intervention: Drug: Zortress® /Everolimus
Outcome Measure: progression of Coronary Artery Calcification
14 Not yet recruiting Delayed CNI-based IMMUNOSUPPRESSION With Advagraf After MELD-based Liver Transplantation
Condition: Liver Graft Dysfunction
Intervention:
Outcome Measures: infection rate (CMV reactivation, wound infection, urinary tract infection, pneumonia);   liver function (LiMAx);   HLA-DR status
15 Recruiting The Impact of Everolimus Based IMMUNOSUPPRESSION in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
Condition: Hepatitis C Recurrence After Liver Transplant
Interventions: Drug: EVL arm;   Drug: MMF arm
Outcome Measures: To compare the liver fibrosis progression (F≥2 under ISHAK score) in patients who receive everolimus vs mTOR free IMMUNOSUPPRESSION;   To identify viral and recipient molecular predictors of fibrosis and anti-HCV treatment responses in liver transplant recipients under steroid-free IMMUNOSUPPRESSION
16 Recruiting Research Study of ATG and Rituximab in Renal Transplantation
Condition: Acute Kidney Injury
Interventions: Drug: ATG;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: MMF
Outcome Measures: Proportion of subjects successfully withdrawn from IMMUNOSUPPRESSION;   The proportion of participants who achieve sirolimus monotherapy;   The proportion of participants who achieve mycophenolate mofetil (MMF/Cellcept®) or mycophenolic acid (Myfortic ®) monotherapy in those participants intolerant of sirolimus.;   Safety endpoints, stratified by sirolimus withdrawal status;   The proportion of participants who achieve either sirolimus or monotherapy;   IMMUNOSUPPRESSION-free duration;   Rejection-free duration;   Proportion of participants with graft loss;   The proportion of participants who die;   The proportion of participants with acute rejection;   The histological severity of biopsies demonstrating acute rejection as measured by Banff Grade;   The proportion of participants with chronic allograft nephropathy;   Time from transplant to the first episode of acute rejection requiring treatment;   The proportion of participants requiring antilymphocyte therapy (OKT3, ATG) for an acute rejection;   Incidence of adverse events, including incidence of post-transplant infections, wound complications, lymphocoele, post-transplant diabetes mellitus, and malignancies;   Renal function as measured by calculated creatinine clearance using the CKDEPI calculator;   Safety, including, renal function, blood pressure, cholesterol level, and glucose control
17 Recruiting Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure
Condition: Renal Transplant Patients After Return to Dialysis
Interventions: Procedure: Transplantectomy within two months after return to dialyse;   Procedure: Progressive reduction of IMMUNOSUPPRESSION. Transplantectomy for cause only
Outcome Measures: Anti HLA Immunization assessed by Luminex assay;   Kinetics anti-HLA antibodies after transplantectomy;   Morbidity and mortality after transplantectomy;   Measuring the impact of systematic transplantectomy on mortality, inflammation, nutritional status, anemia, hypertension and cardiovascular risk factors;   Infectious comorbidity;   Costs of two strategies
18 Recruiting Human Craniomaxillofacial Allotransplantation
Conditions: Facial Injuries;   Traumatic Wounds and Injuries;   Craniofacial Injuries;   Craniofacial Defects
Intervention: Drug: Bone marrow cell-based therapy & 1-drug IMMUNOSUPPRESSION.
Outcome Measures: Graft Survival;   Documentation of IMMUNOSUPPRESSION required by transplanted participants to maintain graft.
19 Recruiting Cardiac Allograft Remodeling and Effects of Sirolimus
Conditions: Cardiac Hypertrophy;   IMMUNOSUPPRESSION
Interventions: Radiation: Cardiac MRI;   Procedure: Coronary angiography with IVUS;   Other: Cardiac Allograft Remodeling;   Drug: M-TOR IMMUNOSUPPRESSION;   Procedure: Cardiac Biopsy C4D stain;   Genetic: Genetic Mechanism of M-TOR;   Other: Cardiopulmonary Exercise Test (CPET)
Outcome Measures: Assessment in left ventricular hypertrophy;   Assess outcomes;   Access outcomes
20 Recruiting A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without IMMUNOSUPPRESSION
Conditions: Gardasil Vaccine;   Stem Cell Transplant;   Immunogenicity;   Quadrivalent HPC Vaccine;   Healthy Volunteers
Intervention: Biological: Gardasil
Outcome Measures: Safety and immunogenicity of Gardasil in HSCT women.;   To determine difference in immune response to Gardasil vaccination in patients on or off IMMUNOSUPPRESSION and between donors and their respective recipients, characterize sexual function and chronic GVHD in HSCT women.

These studies may lead to new treatments and are adding insight into Immunosuppression etiology and treatment.

A major focus of Immunosuppression research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Immunosuppression